◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

Medicenna Therapeutics Corp.

Financial Statements (IFRS) · Amounts in CAD
5 10 All
Income Statement
Balance Sheet
Cash Flow
Line Item FY 2025Mar 31, 2025 FY 2024Mar 31, 2024 FY 2023Mar 31, 2023 FY 2022Mar 31, 2022 FY 2021Mar 31, 2021
Total Revenue 0.00 0.00 0.00 0.00 --
Operating Revenue 0.00 0.00 0.00 0.00 --
Selling General And Administration 5.9M 7.9M 7.0M 7.7M --
General And Administrative Expense 5.9M 7.9M 7.0M 7.7M --
Research And Development 14.4M 10.8M 9.3M 14.7M --
Depreciation And Amortization In Income Statement 55,000 5,000 5,000 37,000 --
Operating Expense 20.4M 18.7M 16.3M 22.5M --
Operating Income -20.4M -18.7M -16.3M -22.5M --
EBIT -20.4M -18.7M -16.3M -22.5M --
Interest Income 1.4M 1.2M 914,000 69,000 --
Interest Income Non Operating 1.4M 1.2M 914,000 69,000 --
Net Interest Income 1.4M 1.2M 914,000 69,000 --
Other Income Expense 7.3M -8.0M 5.3M -173,000 --
Gain On Sale Of Security 7.3M -8.0M 5.3M -173,000 --
Pretax Income -11.8M -25.5M -10.0M -22.6M --
Tax Effect Of Unusual Items 0.00 0.00 0.00 0.00 --
Net Income From Continuing And Discontinued Operation -11.8M -25.5M -10.0M -22.6M --
Net Income From Continuing Operation Net Minority Interest -11.8M -25.5M -10.0M -22.6M --
Net Income Including Noncontrolling Interests -11.8M -25.5M -10.0M -22.6M --
Net Income Common Stockholders -11.8M -25.5M -10.0M -22.6M --
Net Income -11.8M -25.5M -10.0M -22.6M --
EBITDA -20.4M -18.7M -16.3M -22.4M --
Normalized EBITDA -27.6M -10.7M -21.6M -22.3M --
Reconciled Depreciation 53,000 4,000 4,000 38,000 --
Basic EPS -0.15 -0.37 -0.16 -0.42 --
Diluted EPS -0.15 -0.37 -0.16 -0.42 --
Basic Average Shares 76.7M 69.6M 64.7M 54.3M --
Diluted Average Shares 76.7M 69.6M 64.7M 54.3M --
Total Unusual Items 7.3M -8.0M 5.3M -173,000 --
Total Unusual Items Excluding Goodwill 7.3M -8.0M 5.3M -173,000 --
Tax Rate For Calcs 0.00 0.00 0.00 0.00 --
Normalized Income -19.1M -17.5M -15.4M -22.4M --
Depreciation Amortization Depletion Income Statement 55,000 5,000 5,000 37,000 --
Depreciation Income Statement 55,000 5,000 5,000 37,000 --
Diluted NI Availto Com Stockholders -11.8M -25.5M -10.0M -22.6M --
Net Income Continuous Operations -11.8M -25.5M -10.0M -22.6M --
Net Non Operating Interest Income Expense 1.4M 1.2M 914,000 69,000 --
Other Gand A 2.9M 5.5M 5.2M 5.8M --
Salaries And Wages 3.0M 2.3M 1.8M 1.9M --
Total Expenses 20.4M 18.7M 16.3M 22.5M --
Line Item FY 2025Mar 31, 2025 FY 2024Mar 31, 2024 FY 2023Mar 31, 2023 FY 2022Mar 31, 2022 FY 2021Mar 31, 2021
Cash And Cash Equivalents 24.8M 17.0M 33.6M 20.5M --
Cash Cash Equivalents And Short Term Investments 24.8M 17.0M 33.6M 20.5M --
Cash Equivalents 23.6M 11.2M 32.8M 5.0M --
Cash Financial 1.3M 5.8M 796,000 15.5M --
Other Short Term Investments -- -- -- 0.00 10.0M
Receivables 2.7M 1.2M 855,000 1.3M --
Prepaid Assets 639,000 931,000 1.9M 1.5M --
Current Assets 28.2M 19.1M 36.4M 23.4M --
Gross PPE 159,000 0.00 -- 0.00 32,000
Net PPE 159,000 0.00 -- 0.00 32,000
Goodwill And Other Intangible Assets 52,000 57,000 61,000 65,000 --
Total Non Current Assets 211,000 57,000 61,000 65,000 --
Total Assets 28.4M 19.1M 36.4M 23.5M --
Current Debt And Capital Lease Obligation 49,000 -- -- -- 34,000
Accounts Payable 2.7M 2.1M 1.6M 1.7M --
Payables 2.7M 2.1M 1.6M 1.7M --
Payables And Accrued Expenses 4.4M 2.9M 3.8M 2.6M --
Current Accrued Expenses 1.7M 793,000 2.2M 949,000 --
Current Liabilities 4.4M 2.9M 3.8M 2.6M --
Long Term Debt And Capital Lease Obligation 119,000 0.00 -- -- 0.00
Long Term Capital Lease Obligation 119,000 0.00 -- -- 0.00
Total Non Current Liabilities Net Minority Interest 4.9M 11.1M 3.2M 0.00 --
Total Liabilities Net Minority Interest 9.3M 13.9M 7.0M 2.6M --
Common Stock 116.3M 100.9M 100.9M 83.7M --
Capital Stock 116.3M 100.9M 100.9M 83.7M --
Additional Paid In Capital 11.2M 10.7M 9.5M 7.9M --
Retained Earnings -118.3M -106.4M -81.0M -70.9M --
Gains Losses Not Affecting Retained Earnings 3,000 19,000 57,000 171,000 --
Other Equity Adjustments 3,000 19,000 57,000 171,000 --
Common Stock Equity 19.1M 5.2M 29.5M 20.8M --
Stockholders Equity 19.1M 5.2M 29.5M 20.8M --
Total Equity Gross Minority Interest 19.1M 5.2M 29.5M 20.8M --
Total Capitalization 19.1M 5.2M 29.5M 20.8M --
Net Tangible Assets 19.0M 5.1M 29.4M 20.8M --
Tangible Book Value 19.0M 5.1M 29.4M 20.8M --
Working Capital 23.7M 16.2M 32.6M 20.8M --
Invested Capital 19.1M 5.2M 29.5M 20.8M --
Total Debt 168,000 0.00 -- 0.00 34,000
Share Issued 78.2M 69.6M 69.6M 55.6M --
Ordinary Shares Number 78.2M 69.6M 69.6M 55.6M --
Buildings And Improvements 141,000 0.00 -- -- --
Capital Lease Obligations 168,000 0.00 -- 0.00 34,000
Current Capital Lease Obligation 49,000 0.00 -- 0.00 34,000
Derivative Product Liabilities 4.7M 11.1M 3.2M 0.00 --
Other Equity Interest 9.8M -- -- -- --
Other Properties 18,000 -- -- -- 32,000
Other Receivables -- -- -- -- 410,000
Properties 0.00 0.00 -- -- --
Taxes Receivable 2.7M 1.2M 855,000 1.3M --
Line Item FY 2025Mar 31, 2025 FY 2024Mar 31, 2024 FY 2023Mar 31, 2023 FY 2022Mar 31, 2022 FY 2021Mar 31, 2021
Operating Cash Flow -16.5M -16.3M -12.7M -23.6M --
Cash Flow From Continuing Operating Activities -16.5M -16.3M -12.7M -23.6M --
Depreciation And Amortization 53,000 4,000 4,000 38,000 --
Depreciation Amortization Depletion 53,000 4,000 4,000 38,000 --
Stock Based Compensation 2.2M 1.2M 1.4M 1.4M --
Change In Working Capital 1.3M 741,000 2.4M -1.8M --
Change In Receivables -209,000 1.7M 1.2M -392,000 --
Change In Payables And Accrued Expense 1.5M -937,000 1.2M -1.5M --
Other Non Cash Items -1.0M -984,000 -1.2M -737,000 --
Capital Expenditure -33,000 -- -- -- --
Purchase Of PPE -33,000 0.00 -- -- --
Net PPE Purchase And Sale -33,000 0.00 -- -- --
Purchase Of Investment -- -- 0.00 -10.0M -10.0M
Sale Of Investment -- -- 0.00 20.1M 15.0M
Net Investment Purchase And Sale -- -- 0.00 10.1M 5.0M
Investing Cash Flow -33,000 0.00 0.00 10.1M --
Cash Flow From Continuing Investing Activities -33,000 0.00 0.00 10.1M --
Repayment Of Debt -19,000 0.00 0.00 -37,000 --
Net Issuance Payments Of Debt -19,000 0.00 0.00 -37,000 --
Issuance Of Capital Stock 19.7M 0.00 24.8M 3.5M --
Net Common Stock Issuance 19.7M 0.00 24.8M 3.5M --
Financing Cash Flow 23.5M 0.00 24.8M 3.9M --
Cash Flow From Continuing Financing Activities 23.5M 0.00 24.8M 3.9M --
Effect Of Exchange Rate Changes 888,000 -354,000 958,000 -184,000 --
Changes In Cash 7.0M -16.3M 12.1M -9.7M --
Beginning Cash Position 17.0M 33.6M 20.5M 30.4M --
End Cash Position 24.8M 17.0M 33.6M 20.5M --
Free Cash Flow -16.5M -16.3M -12.7M -23.6M --
Common Stock Issuance 19.7M 0.00 24.8M 3.5M --
Depreciation 53,000 4,000 4,000 38,000 --
Gain Loss On Investment Securities -6.3M 7.9M -4.2M -- --
Long Term Debt Payments -19,000 0.00 0.00 -37,000 --
Net Foreign Currency Exchange Gain Loss -904,000 316,000 -1.1M 121,000 --
Net Income From Continuing Operations -11.8M -25.5M -10.0M -22.6M --
Net Long Term Debt Issuance -19,000 0.00 0.00 -37,000 --
Operating Gains Losses -7.3M 8.2M -5.2M 121,000 --
Proceeds From Stock Option Exercised 3.8M 0.00 0.00 406,000 --
NEWS
Loading news...
TRENDING
Loading...